Multiple Sclerosis
Recent clinical, regulatory, research and industry developments relating to this disease.
Neuroinflammation across neurological diseases.
Market withdrawal: Extavia (EMA)
A disease-specific convergence of host and Epstein-Barr virus genetics in multiple sclerosis.
The role of the adaptive immune system in the initiation and persistence of multiple sclerosis.
Role of innate immune cells in multiple sclerosis.
Exploring the Pathophysiology, Diagnosis, and Treatment Options of Multiple Sclerosis.
The Influence of SARS-CoV-2 Infection on the Development of Selected Neurological Diseases.
Approval: Dimethyl fumarate Accord (EMA)
Approval: Dimethyl fumarate Mylan (EMA)
Approval: Dimethyl fumarate Neuraxpharm (EMA)
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 1 regulatory approval from EMA on record.
- 6 clinical trials expected to report results, the earliest in Q4 2026.
- 3 industry developments reported.
- Q4 2026A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-1)
- Q4 2026A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-2)
- Q1 2030Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)
- Q4 2030A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Remibrutinib in Patients With Secondary Progressive Multiple Sclerosis
- Q2 2031A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
Clinical MilestonesView all 16Hide
- 2026-05-19Open-Label, Randomized, Multicenter, Multiple-Dose, Active-Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label ExtensionResults posted
- 2026-02-27AGNOS: An 18-month, Open-label, Multi-Center Phase IV Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Naïve, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes.Results posted
- 2026-07-13A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Remibrutinib in Patients With Secondary Progressive Multiple SclerosisResults expected Q4 2030
- 2026-07-08Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)Results expected Q1 2030
- 2026-06-23A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple SclerosisResults expected Q2 2031
- 2026-06-18An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple SclerosisResults expected Q2 2032
- 2026-02-23A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 Versus Placebo in Adults With Relapsing Multiple Sclerosis (ENSURE-1)Results expected Q4 2026
- 2025-11-14A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS)Completed
- 2025-11-11An Open-Label, Prospective, Single-arm, Multi-center Study to Assess Disease Activity and Biomarkers of Neuronal Damage in Minority Patients With Relapsing Multiple Sclerosis Receiving Treatment With OcrelizumabCompleted
- 2025-11-04Open-Label Rater-Blind Randomized Multi-Center Parallel-Arm Active- Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC Monthly vs. First Line DMT - Physician's Choice in the Treatment of Newly Diagnosed RMSCompleted
- 2027-01-01A Randomized, Placebo-Controlled, Parallel-Group Study in Pediatric Subjects Ages 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 for the Treatment of Relapsing-Remitting Forms of Multiple SclerosisWithdrawn
- 2026-04-03A Phase III Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Neuromyelitis Optica Spectrum Disorders.Terminated
- 2026-01-31Open-Label Multicenter Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple SclerosisWithdrawn
- 2025-11-28Autologous Hematopoietic Stem Cell Transplant for Neuromyelitis Optica Spectrum Disorder (NMOSD)Withdrawn
- 2025-09-08A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Paediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifying Therapy (DMT)Terminated
Industry & MarketViewHide
- 2026-07-15STAT+: New study untangles how Epstein-Barr viral infection triggers immune response in multiple sclerosisResearch news · STAT News
- 2026-07-15Biologists pinpoint how common virus triggers multiple sclerosisIndustry · Nature News
- 2026-06-29These fat-filled brain cells may be making multiple sclerosis worseIndustry · Science Daily
Regulatory UpdatesViewHide
- 2026-06-19Approval — TolebrutinibCenrifki is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) without relapses in the last 2 years.
- 2027-01-01ClinicalA Randomized, Placebo-Controlled, Parallel-Group Study in Pediatric Subjects Ages 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 for the Treatment of Relapsing-Remitting Forms of Multiple SclerosisWithdrawn
- 2026-07-15IndustrySTAT+: New study untangles how Epstein-Barr viral infection triggers immune response in multiple sclerosisResearch news · STAT News
- 2026-07-15IndustryBiologists pinpoint how common virus triggers multiple sclerosisIndustry · Nature News
- 2026-07-13ClinicalA Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Remibrutinib in Patients With Secondary Progressive Multiple SclerosisResults expected Q4 2030
- 2026-07-08ClinicalUblituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)Results expected Q1 2030
- 2026-06-29IndustryThese fat-filled brain cells may be making multiple sclerosis worseIndustry · Science Daily
- 2026-06-23ClinicalA Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple SclerosisResults expected Q2 2031
- 2026-06-19RegulatoryApproval — TolebrutinibCenrifki is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) without relapses in the last 2 years.
- 2026-06-18ClinicalAn Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple SclerosisResults expected Q2 2032
- 2026-05-19ClinicalOpen-Label, Randomized, Multicenter, Multiple-Dose, Active-Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label ExtensionResults posted
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Cenrifki is indicated for the treatment of adult patients with secondary progressive mult… (2026)
Approval — Riulvy is indicated for the treatment of adult and paediatric patients aged 13 years and… (2025)
Approval — Dimethyl fumarate Mylan is indicated for the treatment of adult and paediatric patients a… (2024)
Approval — Tyruko is indicated as single disease modifying therapy in adults with highly active rela… (2023)
Approval — Briumvi is indicated for the treatment of adult patients with relapsing forms of multiple… (2023)
Approval — Teriflunomide Accord is indicated for the treatment of adult patients and paediatric pati… (2022)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Multiple Sclerosis40
- Alzheimer Disease6
- Gastrointestinal Microbiome6
- Encephalomyelitis, Autoimmune, Experimental5
- Brain4
- Neurodegenerative Diseases4
- Parkinson Disease4
- Autoimmune Diseases3
Leading journals6
- Frontiers in immunology4
- International journal of molecular sciences4
- Gut microbes3
- Neurology3
- Proceedings of the National Academy of Sciences of the United States of America3
- Cells2
Leading researchers8
- Barkhof F3
- Baranzini SE2
- Clarke JWE2
- Cole JH2
- Ding Y2
- Kuhle J2
- Levin MC2
- Li H2
Affiliations (unnormalised)6
- Center for Molecular Medicine2
- College of Medicine2
- College of Pharmacy2
- Imperial College London2
- Karolinska Institutet2
- Lerner Research Institute2
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Multiple sclerosis is an autoimmune disorder of the central nervous system that primarily affects young adults. It is characterized by sharply demarcated areas of demyelination in the white matter and by a clinical course that often involves recurrent attacks with partial recovery, although acute fulminating and chronic progressive forms also occur.
The underlying cause of multiple sclerosis is not fully defined in the supplied material. The literature grounding supports complex gene-environment interactions, with epidemiologic associations involving low vitamin D levels, smoking, childhood obesity, and Epstein-Barr virus infection.
Multiple sclerosis is an inflammatory demyelinating disease in which immune-mediated injury targets myelin in the central nervous system. The grounding also supports roles for cytokine and interleukin signaling, innate immunity, oxidative stress, signal transduction, and impaired remyelination, with some literature debating whether neurodegeneration contributes to irreversible disability.
The supplied literature identifies low serum vitamin D, smoking, childhood obesity, and Epstein-Barr virus infection as likely risk factors for disease development. Genetic susceptibility is also supported by the grounding through polymorphism and quantitative trait loci.
The grounding supports disease-modifying treatment at the drug-class level, including immunomodulatory therapy such as glatiramer acetate. It also supports broader treatment approaches aimed at controlling inflammatory disease activity and addressing relapsing or progressive clinical courses, but does not provide enough detail to specify additional standard modalities beyond this.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.